<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114111">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617681</url>
  </required_header>
  <id_info>
    <org_study_id>CVAL489K2306</org_study_id>
    <secondary_id>2011-005991-40</secondary_id>
    <nct_id>NCT01617681</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD</brief_title>
  <official_title>A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Without Chronic Kidney Disease, Followed by a 20 Week Open-label Titration Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess efficacy, safety and tolerability of valsartan when comparing two doses of
      valsartan in reducing and controlling blood pressure in children with hypertension with or
      without CKD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2012</start_date>
  <completion_date type="Actual">January 24, 2017</completion_date>
  <primary_completion_date type="Actual">January 24, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline (Week 0) in mean systolic blood pressure (MSBP) at Week 6 endpoint</measure>
    <time_frame>Baseline, week 6</time_frame>
    <description>Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) for that visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean diastolic blood pressure (MDBP) at Week 6 and end of study (26 weeks)</measure>
    <time_frame>6 weeks, 26 weeks</time_frame>
    <description>Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) for that visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving MSBP &lt; 90th percentile for age, gender and height at Week 6 endpoint and end of study (26 weeks)</measure>
    <time_frame>6 weeks, 26 weeks</time_frame>
    <description>Patient's blood pressure will be measured in the same position at every visit Systolic and diastolic blood pressures will be measured three times at 2-3 minute intervals. The arithmetic mean of these three blood pressure measurements will be used as the mean office blood pressure (MSBP and MDBP) for that visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Urine Albumin Creatinine Ratio (UACR) response at Week 6 endpoint and end of study (26 weeks)</measure>
    <time_frame>6 weeks, 26 weeks</time_frame>
    <description>UACR response is defined as percentage change from baseline in UACR≤ 25%. UACR [mg/mmol] = urine albumin [mg/L] / urine creatinine [mmol/L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>26 weeks</time_frame>
    <description>Patients safety will be based on frequency of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Pediatric Hypertension With or Without CKD</condition>
  <arm_group>
    <arm_group_label>Valsartan 0.25 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAL489</intervention_name>
    <description>Valsartan 3mg/kg oral solution</description>
    <arm_group_label>Valsartan 0.25 mg/kg</arm_group_label>
    <arm_group_label>Valsartan 4 mg/kg</arm_group_label>
    <arm_group_label>Valsartan 1 mg/kg</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAL489 matching placebo</intervention_name>
    <description>Valsartan 3 mg/kg oral solution</description>
    <arm_group_label>Valsartan 0.25 mg/kg</arm_group_label>
    <arm_group_label>Valsartan 4 mg/kg</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients eligible for inclusion in this study have to fulfill all of the following
        criteria:

        Have the ability to provide written informed consent; Have at baseline , a documented
        diagnosis of hypertension (as defined in the National High Blood Pressure Education
        Program 2004); MSBP (mean of 3 measurements) must be ≥95th percentile, and ≤25% above the
        95th percentile, for age, gender and height, at baseline; CKD patients must be defined as
        any of the following criteria: Kidney damage for ≥3 months, as defined by structural or
        functional abnormalities of the kidney, with or without decreased GFR, manifested by one
        or more of the following features: Abnormalities in the composition of urine,
        Abnormalities in imaging tests, Abnormalities on kidney biopsy, Estimated eGFR &lt;60
        mL/min/1.73m2 for ≥3 months, with or without the other signs of kidney damage described
        above; Able to swallow the valsartan solution; Body weight must be ≥8 kg and ≤40 kg at
        baseline; Must be able to safely washout from other antihypertensive therapy (if
        applicable) Exclusion criteria AST/SGOT or ALT/SGPT &gt;3 times the upper limit of the
        reference range; Estimated Glomerular Filtration Rate [eGFR] &lt;30 mL/min/1.73m² (calculated
        using Modified Schwartz Formula); Serum potassium &gt;5.3 mmol/L; Uncontrolled diabetes
        mellitus, as defined by the investigator; Unilateral, bilateral and graft renal artery
        stenosis; Current diagnosis of heart failure (NYHA Class II-IV); Patients taking any of
        the following concomitant medications following screening: RAAS blockers other than study
        drug, Lithium, Potassium-sparing diuretics, potassium supplements, salt substitutes
        containing potassium and other substances that may increase potassium levels;
        Non-steroidal anti-inflammatory drugs (NSAIDS), including selective COX-2 inhibitors,
        acetylsalicylic acid &gt;3g/day, and non-selective NSAIDs (paracetamol/acetaminophen is
        permitted); Antidepressant drugs in the class of MAO inhibitors (e.g. phenelzine); Chronic
        use of stimulant therapy for ADD/ADHD; patients who have coarctation of the aorta with a
        gradient of ≥30 mmHg; Previous solid organ transplantation except renal transplantation.
        Renal transplant must have occurred at least 1 year prior to enrollment; Patient must be
        on stable doses of immunosuppressive therapy and deemed clinically stable by the
        investigator; Patients known to be positive for the human immunodeficiency virus (HIV)
        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitibia</city>
        <state>Parana</state>
        <zip>80250-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <zip>13087-567</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caxias do Sul</city>
        <zip>95070-561</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala</city>
        <zip>1010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H 1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <zip>90134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vinius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-154</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>June 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension; CKD; Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
